Emcure Pharmaceuticals secures 100% control of Gennova with ₹231.87 crore final stake buy.
Emcure is acquiring the final 12.05% minority stake in Gennova for ₹231.87 crore, making it a 100% subsidiary. The move streamlines leadership and simplifies ownership to accelerate growth in the…
Read the full articleYou might also wanna read
Emcure consolidates stake in Gennova, under stewardship of promoter family scion
Gennova is a ₹49-crore company and it mRNA business, at ₹6.47 crore, represented 0.71% of consolidated revenue of the company of ₹911.58 cro
Emcure subsidiary Gennova to transfer mRNA business to Immunoscript Life Science for ₹139 crore
Gennova brought out India’s first mRNA Covid vaccine
Mylan to sell up to $363 million stake in India’s Biocon, term sheet shows
SINGAPORE, July 13 (Reuters) - Mylan Inc plans to sell up to 92 million shares in Indian drugmaker Biocon Ltd, worth up to 34.81 billion Ind
Merck KGaA acquires Bio-Techne in $11 billion all-cash deal to bolster life sciences division
All-cash deal will strengthen the German company’s life sciences portfolio
cen.acs.org·20d agoBiocon block deal today: Mylan may sell Rs 3,481 crore worth of shares in pharma major
According to Business Today sources, the floor price has been set at Rs 378.50 per share, a 7.9 per cent discount to Biocon's Monday closing
Humana exits $900M position in end-of-life provider Gentiva
The Kentucky-based insurance giant had owned a 40% stake in the hospice company, stemming from its 2021 acquisition of Kindred Healthcare. H
Comments
Sign in to join the conversation.
No comments yet. Be the first.